Drug Target Identification Using Side-Effect Similarity
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Targets for drugs have so far been predicted on the basis of molecular or cellular features, for example, by exploiting similarity in chemical structure or in activity across cell lines. We used phenotypic side-effect similarities to infer whether two drugs share a target. Applied to 746 marketed drugs, a network of 1018 side effect–driven drug-drug relations became apparent, 261 of which are formed by chemically dissimilar drugs from different therapeutic indications. We experimentally tested 20 of these unexpected drug-drug relations and validated 13 implied drug-target relations by in vitro binding assays, of which 11 reveal inhibition constants equal to less than 10 micromolar. Nine of these were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The work of Campillios et al. previously suggested the similarity of two drugs’ side effect profiles is positively correlated with the probability that these drugs share a common target28.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [28]
Citations
Cites
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Gohlke, H., & Klebe, G. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020802)41:15<2644::aid-anie2644>3.0.co;2-o · Cited by 843
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Do Structurally Similar Molecules Have Similar Biological Activity?
Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020155c · Cited by 806
SuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647
Self-citation
Research works printed but not linked: 3
- J. Blagg, Annu. Rep. Med. Chem.41, 353 (2006).
- S. Guntheret al., Nucleic Acids Res.36, D919 (2008).
- C. M. Krejsaet al., Curr. Opin. Drug Discov. Dev.6, 470 (2003).
Cited by
Network medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
“That is, a drug might have more than one binding partner such that its efficacy is determined by its multiple interactions, leading to unwanted side effect”
BackgroundDrug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Extensive impact of non-antibiotic drugs on human gut bacteria
Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E. E., Brochado, A. R., Fernandez, K. C., Dose, H., Mori, H., et al. (2018) · Nature · doi:10.1038/nature25979 · Cited by 1,905
“Drugs with less than seven associated SEs were discarded 59.”
Self-citationSwissTargetPrediction: a web server for target prediction of bioactive small molecules
Gfeller, D., Grosdidier, A., Wirth, M., Daina, A., Michielin, O., & Zoete, V. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku293 · Cited by 1,791
“SwissTargetPrediction is based on the observation that similar bioactive molecules are more likely to share similar targets (1,21).”
BackgroundPredicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Modeling polypharmacy side effects with graph convolutional networks
Zitnik, M., Agrawal, M., & Leskovec, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty294 · Cited by 1,501
The SIDER database of drugs and side effects
Kuhn, M., Letunic, I., Jensen, L. J., & Bork, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1075 · Cited by 1,451
“For example, it was shown that ADRs can be used to predict drug targets (1) and that causal relations between targets and ADRs can be elucidated (2,3).”
BackgroundSelf-citationTarget identification and mechanism of action in chemical biology and drug discovery
Schenone, M., Dančík, V., Wagner, B. K., & Clemons, P. A. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1199 · Cited by 1,096
Target identification using drug affinity responsive target stability (DARTS)
Lomenick, B., Hao, R., Jonai, N., Chin, R. M., Aghajan, M., Warburton, S., Wang, J., Wu, R. P., Gomez, F., Loo, J. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910040106 · Cited by 1,095
“Developing new methods for drug target identification is an area of intense interest, and both experimental and computational approaches have been developed (28, 29).”
MethodConcepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis
Shimada, K., Skouta, R., Kaplan, A., Yang, W. S., Hayano, M., Dixon, S. J., Brown, L. M., Valenzuela, C. A., Wolpaw, A. J., & Stockwell, B. R. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2079 · Cited by 1,017
Liu, X., Ouyang, S., Yu, B., Liu, Y., Huang, K., Gong, J., Zheng, S., Li, Z., Li, H., & Jiang, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq300 · Cited by 967
Gaussian interaction profile kernels for predicting drug–target interaction
van Laarhoven, T., Nabuurs, S. B., & Marchiori, E. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr500 · Cited by 934
Data-driven prediction of drug effects and interactions
Tatonetti, N. P., Ye, P. P., Daneshjou, R., & Altman, R. B. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003377 · Cited by 936
“Nonetheless, recent work in chemical biology has used the SIDER (a text-mined database of drug package inserts) to good effect ( 12 , 13 , 20 ).”
BackgroundMethodInfluentialLuo, Y., Zhao, X., Zhou, J., Yang, J., Zhang, Y., Kuang, W., Peng, J., Chen, L., & Zeng, J. (2017) · Nature Communications · doi:10.1038/s41467-017-00680-8 · Cited by 916
“In addition to chemical and genomic data, previous works have incorporated pharmacological or phenotypic information, such as side-effect [7, 41], transcriptional response data [24], drug-disease associations [70], public gene expression data [18, 53] and functional data [77] for DTI prediction.”
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
“Shortest path and random walk analysis, as well as the identification of tight clusters, bridges and bottlenecks of these networks (Campillos et al., 2008; Yamanishi et al., 2010; Oprea et al., 2011; Takarabe et al., 2012) combined with the selective optimization of side activities (Wermuth, 2006)…”
BackgroundMethodInfluentialA side effect resource to capture phenotypic effects of drugs
Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J., & Bork, P. (2010) · Molecular Systems Biology · doi:10.1038/msb.2009.98 · Cited by 899
“The extraction procedure is based on the method used in Campillos et al (2008).”
BackgroundMethodInfluentialSelf-citationLarge-scale prediction and testing of drug activity on side-effect targets
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., et al. (2012) · Nature · doi:10.1038/nature11159 · Cited by 881
Automated design of ligands to polypharmacological profiles
Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X.-P., Norval, S., Sassano, M. F., Shin, A. I., Webster, L. A., et al. (2012) · Nature · doi:10.1038/nature11691 · Cited by 832
BATMAN-TCM: a Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine
Liu, Z., Guo, F., Wang, Y., Li, C., Zhang, X., Li, H., Diao, L., Gu, J., Wang, W., Li, D., et al. (2016) · Scientific Reports · doi:10.1038/srep21146 · Cited by 821
“Recently, as the emergence of databases for herbal ingredients (e.g. 12 ], more and more evidence indicates that combining target prediction of herbal ingredients and subsequent network pharmacology analyses is a feasible and powerful way to analyze the molecular mechanism of TCM 13–18 .”
BackgroundPrediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference
Cheng, F., Liu, C., Jiang, J., Lu, W., Li, W., Liu, G., Zhou, W., Huang, J., & Tang, Y. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002503 · Cited by 818
“Campillos et al. identified new DTIs using side-effect similarity [13].”
MethodDiscovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
“Prediction of drug MoA has been attempted by using gene expression profiles following drug treatment (7 – 13), by comparing side-effect similarities (14), by text-mining literature (15), or by applying chemoinformatic tools to search for small molecules similarities (16, 17).”
Sirota, M., Dudley, J. T., Kim, J., Chiang, A. P., Morgan, A. A., Sweet-Cordero, A., Sage, J., & Butte, A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001318 · Cited by 799
Zitnik, M., Nguyen, F., Wang, B., Leskovec, J., Goldenberg, A., & Hoffman, M. M. (2019) · Information Fusion · doi:10.1016/j.inffus.2018.09.012 · Cited by 675
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
“…Iorio et al., 2013 ), protein interactions ( Guney et al., 2016 ), genetic association ( Nelson et al., 2015 ; Sanseau et al., 2012 ), drug side effects ( Campillos et al., 2008 ; Nugent et al., 2016 ), disease symptoms ( Zhou et al., 2014 ), and molecular pathways ( Pratanwanich and Lio´, 2014 ).”
BackgroundHuman symptoms–disease network
Zhou, X., Menche, J., Barabási, A.-L., & Sharma, A. (2014) · Nature Communications · doi:10.1038/ncomms5212 · Cited by 653
Drug–target interaction prediction: databases, web servers and computational models
Chen, X., Yan, C. C., Zhang, X., Zhang, X., Dai, F., Yin, J., & Zhang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv066 · Cited by 658
Supervised prediction of drug–target interactions using bipartite local models
Bleakley, K., & Yamanishi, Y. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp433 · Cited by 628
“Another interesting approach by Campillos et al. (2008) was the use of similarities in the sideeffects of known drugs to predict new drug-target interactions, some of which were verified by in vitro binding assays.”
BackgroundInfluentialNetwork-based in silico drug efficacy screening
Guney, E., Menche, J., Vidal, M., & Barábasi, A.-L. (2016) · Nature Communications · doi:10.1038/ncomms10331 · Cited by 625
“The increasing interest in reusing existing drugs for novel therapies has recently given rise to various approaches that aim to identify candidate drugs with similar characteristics to known drugs used in a disease 7,8,19–20 .”
BackgroundDeep-Learning-Based Drug–Target Interaction Prediction
Wen, M., Zhang, Z., Niu, S., Sha, H., Yang, R., Yun, Y., & Lu, H. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00618 · Cited by 576
Yao, Z.-J., Dong, J., Che, Y.-J., Zhu, M.-F., Wen, M., Wang, N.-N., Wang, S., Lu, A.-P., & Cao, D.-S. (2016) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-016-9915-2 · Cited by 514
Exploiting drug-disease relationships for computational drug repositioning
Dudley, J. T., Deshpande, T., & Butte, A. J. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr013 · Cited by 524
“[42] performed a systematic analysis to identify novel drug–target relationships for 746 approved drugs using a side effect similarity approach.”
BackgroundDrug–target interaction prediction by random walk on the heterogeneous network
Chen, X., Liu, M.-X., & Yan, G.-Y. (2012) · Molecular BioSystems · doi:10.1039/c2mb00002d · Cited by 533
He, T., Heidemeyer, M., Ban, F., Cherkasov, A., & Ester, M. (2017) · Journal of Cheminformatics · doi:10.1186/s13321-017-0209-z · Cited by 509
“These approaches can again be divided into two types which are target-based approaches [12–14] and ligand-based approaches [15–18].”
BackgroundNetwork analyses in systems pharmacology
Berger, S. I., & Iyengar, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp465 · Cited by 510
“Campillos et al. constructed a network of drugs connected if they shared both a degree of structural similarity and similar side effect profiles (Campillos et al., 2008).”
BackgroundShaping the interaction landscape of bioactive molecules
Gfeller, D., Michielin, O., & Zoete, V. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt540 · Cited by 501
Protein promiscuity and its implications for biotechnology
Nobeli, I., Favia, A. D., & Thornton, J. M. (2009) · Nature Biotechnology · doi:10.1038/nbt1519 · Cited by 497
“Considerable effort is being put now into computationa”
BackgroundPolypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 479
Artificial intelligence in cancer target identification and drug discovery
You, Y., Lai, X., Pan, Y., Zheng, H., Vera, J., Liu, S., Deng, S., & Zhang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00994-0 · Cited by 435
Yamanishi, Y., Kotera, M., Kanehisa, M., & Goto, S. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq176 · Cited by 470
“The identification of drug–target interactions (interactions between drugs and target proteins) is a key area in genomic drug discovery.”
BackgroundMachine learning approaches and databases for prediction of drug–target interaction: a survey paper
Bagherian, M., Sabeti, E., Wang, K., Sartor, M. A., Nikolovska-Coleska, Z., & Najarian, K. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbz157 · Cited by 429
“…DTI using various types of biological data such as chemical structures, protein domain and drug side effects (note that studies that primarily focused on side effect are excluded in this paper [ 59–62]) and three supervised algorithms (BGL [13, 143], BLM [101] and pairwise kernel regression [9]).”
BackgroundMethodSimilarity-based machine learning methods for predicting drug–target interactions: a brief review
Ding, H., Takigawa, I., Mamitsuka, H., & Zhu, S. (2014) · Briefings in Bioinformatics · doi:10.1093/bib/bbt056 · Cited by 427
Jin, G., & Wong, S. T. C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.005 · Cited by 416
Deep learning in drug discovery: an integrative review and future challenges
Askr, H., Elgeldawi, E., Aboul Ella, H., Elshaier, Y. A. M. M., Gomaa, M. M., & Hassanien, A. E. (2023) · Artificial Intelligence Review · doi:10.1007/s10462-022-10306-1 · Cited by 390
ChemDes: an integrated web-based platform for molecular descriptor and fingerprint computation
Dong, J., Cao, D.-S., Miao, H.-Y., Liu, S., Deng, B.-C., Yun, Y.-H., Wang, N.-N., Lu, A.-P., Zeng, W.-B., & Chen, A. F. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0109-z · Cited by 404
“For example, Bork et al. [17] successfully identified certain potential targets by combining the chemical similarity and side-effect similarity.”
BackgroundSemi-supervised drug-protein interaction prediction from heterogeneous biological spaces
Xia, Z., Wu, L.-Y., Zhou, X., & Wong, S. T. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-s2-s6 · Cited by 389
“Our future work, will incorporate more sophisticated and biologically relevant information into the kernel similarity, such as side effect [15], to improve the prediction accuracy.”
Drug–target interaction prediction by learning from local information and neighbors
Mei, J.-P., Kwoh, C.-K., Yang, P., Li, X.-L., & Zheng, J. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts670 · Cited by 382
“inferring interactions from the drug similarity or target similarity, network-based inference was also studied in Cheng et al. (2012), which infers or predicts drug–target interactions based on the topology of the known interaction network.”
BackgroundMethodInfluentialJarada, T. N., Rokne, J. G., & Alhajj, R. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00450-7 · Cited by 384
Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378
“A relatively small number of ion channels (31) are categorized as Tdark (TABLE 1).”
BackgroundSelf-citationComputational Drug Repositioning: From Data to Therapeutics
Hurle, M. R., Yang, L., Xie, Q., Rajpal, D. K., Sanseau, P., & Agarwal, P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.1 · Cited by 373
“26 Recent computational methods have leveraged these data and automated the approaches to predict new therapies.”
MethodL1000CDS2: LINCS L1000 characteristic direction signatures search engine
Duan, Q., Reid, S. P., Clark, N. R., Wang, Z., Fernandez, N. F., Rouillard, A. D., Readhead, B., Tritsch, S. R., Hodos, R., Hafner, M., et al. (2016) · npj Systems Biology and Applications · doi:10.1038/npjsba.2016.15 · Cited by 355
Targeting Breast Cancer Stem Cells
Liu, S., & Wicha, M. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5388 · Cited by 356
Improving compound–protein interaction prediction by building up highly credible negative samples
Liu, H., Sun, J., Guan, J., Zheng, J., & Zhou, S. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv256 · Cited by 359
“…including the drug expression profiles (Carrella et al ., 2014; Iorio et al ., 2010; Wolpaw et al ., 2011), functional groups (He et al ., 2010) and side effects (Campillos et al ., 2008; Mizutani et al ., 2012) of drugs, signaling pathways and GO annotations (Jaeger et al ., 2014) of proteins…”
Computational/in silico methods in drug target and lead prediction
Agamah, F. E., Mazandu, G. K., Hassan, R., Bope, C. D., Thomford, N. E., Ghansah, A., & Chimusa, E. R. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz103 · Cited by 328
“For example, sildenafil initially developed to treat angina expressed a side effect of prolonged penile erection, and this resulted in a change of the treatment focus of the drug [90].”
BackgroundTarget identification among known drugs by deep learning from heterogeneous networks
Zeng, X., Zhu, S., Lu, W., Liu, Z., Huang, J., Zhou, Y., Fang, J., Huang, Y., Guo, H., Li, L., et al. (2020) · Chemical Science · doi:10.1039/c9sc04336e · Cited by 357
In silico methods for drug repurposing and pharmacology
Hodos, R. A., Kidd, B. A., Shameer, K., Readhead, B. P., & Dudley, J. T. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1337 · Cited by 326
Drug repositioning by integrating target information through a heterogeneous network model
Wang, W., Yang, S., Zhang, X., & Li, J. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu403 · Cited by 335
“Received on February 11, 2014; revised on May 30, 2014; accepted on June 23, 2014”
BackgroundProperties and identification of human protein drug targets
Bakheet, T. M., & Doig, A. J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp002 · Cited by 324
“Drug targets may also be identified via side effect similarity (Campillos et al., 2008). Here, we report a number of properties of human drug targets that differ significantly from non-drug targets and apply these to identify new potential drug targets. Previous work on categorizing drug targets has considered biologi…”
BackgroundThe significance of artificial intelligence in drug delivery system design
Hassanzadeh, P., Atyabi, F., & Dinarvand, R. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.001 · Cited by 305
Ezzat, A., Wu, M., Li, X.-L., & Kwoh, C.-K. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby002 · Cited by 314
Discovering Anti-Cancer Drugs via Computational Methods
Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y., & Yuan, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00733 · Cited by 307
“Interestingly, a method proposed by Campillos et al. that uses the similarity of drug side effects to determine whether multiple drugs could interact with the same target proteins attracted our attention (Campillos et al., 2008).”
MethodHuman Disease-Drug Network Based on Genomic Expression Profiles
Hu, G., & Agarwal, P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006536 · Cited by 310
“For the drug-drug relationship and target deconvolution, we can integrate the results derived from assessing drug side-effect and chemical similarity, target sequence similarity and drug-target network [4,12,60].”
MethodErratum: Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.52 · Cited by 311
Self-citationSystems biology and the future of medicine
Loscalzo, J., & Barabasi, A. (2011) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.144 · Cited by 287
Artificial intelligence for drug discovery: Resources, methods, and applications
Chen, W., Liu, X., Zhang, S., & Chen, S. (2023) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2023.02.019 · Cited by 273
“The Side Effect Resource (SIDER) is a database that focuses on drugs and their side effects.(15) The current release of SIDER includes 1,430 drugs, 5,880 side effects, and 140,064 drug-side effect pairs.”
BackgroundDrug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 294
Liu, M., Wu, Y., Chen, Y., Sun, J., Zhao, Z., Chen, X.-W., Matheny, M. E., & Xu, H. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000699 · Cited by 289
Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery
Pérot, S., Sperandio, O., Miteva, M. A., Camproux, A.-C., & Villoutreix, B. O. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.015 · Cited by 276
Similarity-based modeling in large-scale prediction of drug-drug interactions
Vilar, S., Uriarte, E., Santana, L., Lorberbaum, T., Hripcsak, G., Friedman, C., & Tatonetti, N. P. (2014) · Nature Protocols · doi:10.1038/nprot.2014.151 · Cited by 280
“The same idea can be expanded to codify, for each drug, its known targets (target fingerprints) or the adverse effects already described (ADE fingerprints) 12,13 .”
BackgroundDrug repurposing: far beyond new targets for old drugs
Oprea, T. I., & Mestres, J. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9390-1 · Cited by 285
A Bayesian machine learning approach for drug target identification using diverse data types
Madhukar, N. S., Khade, P. K., Huang, L., Gayvert, K., Galletti, G., Stogniew, M., Allen, J. E., Giannakakou, P., & Elemento, O. (2019) · Nature Communications · doi:10.1038/s41467-019-12928-6 · Cited by 265
Feng, Y., Mitchison, T. J., Bender, A., Young, D. W., & Tallarico, J. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2876 · Cited by 279
“Another fascinating example of data integration was the use of a database of side effects of approved drugs together with measurements of chemical similarity to infer off-target drug interactions in human”
BackgroundNetwork-Based Relating Pharmacological and Genomic Spaces for Drug Target Identification
Zhao, S., & Li, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011764 · Cited by 277
“Interactions with a Ki binding affinity lower than 10mM were viewed as drug-target interactions [5].”
BackgroundThe role of ontologies in biological and biomedical research: a functional perspective
Hoehndorf, R., Schofield, P. N., & Gkoutos, G. V. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv011 · Cited by 264
“Text mining based on ontologies has been used to identify the presence of disease modules based on phenotypes [61, 62], drug targets and drug indications [63, 74], drug–drug interaction [65] and candidate genes for diseases [66, 67].”
MethodSystematic Drug Repositioning Based on Clinical Side-Effects
Yang, L., & Agarwal, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028025 · Cited by 266
“In silico methodologies have helped in mining the drug’s off-target effects [3,4,5,6,7,8], off-system effects (such as, offtarget related gene expression perturbation or downstream pathways) [9,10,11,12,13] and off-phenotypes (i.”
BackgroundMethodDrug repositioning for personalized medicine
Li, Y. Y., & Jones, S. J. (2012) · Genome Medicine · doi:10.1186/gm326 · Cited by 248
“Most methods are based on similarity, between drugs [74], proteins [75], or side effect phenotypes [76].”
MethodXie, L., Li, J., Xie, L., & Bourne, P. E. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000387 · Cited by 247
“Chemogenomics has emerged as a new discipline to systematically establish target relationships based on the structural and biological similarity of their ligands [3,11–18].”
BackgroundNetwork-Based Methods for Prediction of Drug-Target Interactions
Wu, Z., Li, W., Liu, G., & Tang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01134 · Cited by 237
ChemoPy: freely available python package for computational biology and chemoinformatics
Cao, D.-S., Xu, Q.-S., Hu, Q.-N., & Liang, Y.-Z. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt105 · Cited by 239
“…were widely used to characterize ligand molecules in the protein–ligand network and predict new protein–ligand associations to identify potential drug targets (Campillos et al ., 2008; Cao et al ., 2012a, b; Chou et al ., 2006; Izrailev et al ., 2004; Keiser et al ., 2007; Prado-Prado et al .,…”
MethodLabel Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects
Zhang, P., Wang, F., Hu, J., & Sorrentino, R. (2015) · Scientific Reports · doi:10.1038/srep12339 · Cited by 242
“The advantages of leveraging clinical phenotypic information lies on two aspects: (1) clinical phenotypic information could serve as biomarkers for both therapeutic effects 16,17 and toxic effect 18 , thus has potential to be used in DDI predictions.”
BackgroundLiterature mining, ontologies and information visualization for drug repurposing
Andronis, C., Sharma, A., Virvilis, V., Deftereos, S., & Persidis, A. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr005 · Cited by 234
“[87] predicted novel targets for existing drugs by looking at the side effect similarity of otherwise unrelated drugs.”
BackgroundYang, P.-Y., Liu, K., Ngai, M. H., Lear, M. J., Wenk, M. R., & Yao, S. Q. (2010) · Journal of the American Chemical Society · doi:10.1021/ja907716f · Cited by 229
Predicting drug side-effect profiles: a chemical fragment-based approach
Pauwels, E., Stoven, V., & Yamanishi, Y. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-169 · Cited by 231
“In a pioneer work to illustrate this concept, it has been shown that drugs with similar sideeffects tend to share similar profiles of protein targets [8].”
BackgroundText-mining solutions for biomedical research: enabling integrative biology
Rebholz-Schuhmann, D., Oellrich, A., & Hoehndorf, R. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3337 · Cited by 225
“Another study identified terms from a phenotype ontology for drug labels and used the results to define a similarity measure between side effects 88 .”
BackgroundOlayan, R. S., Ashoor, H., & Bajic, V. B. (2018) · Bioinformatics · doi:10.1093/bioinformatics/btx731 · Cited by 231
“…similarity improves the prediction of DTIs, where the assumption is that drugs with similar target protein binding profiles tend to cause similar side-effects, implying a direct correlation between target protein binding and side-effect similarity (Campillos et al., 2008; Vilar and Hripcsak, 2016).”
BackgroundComputational approaches to identifying and characterizing protein binding sites for ligand design
Henrich, S., Salo‐Ahen, O. M. H., Huang, B., Rippmann, F. F., Cruciani, G., & Wade, R. C. (2010) · Journal of Molecular Recognition · doi:10.1002/jmr.984 · Cited by 223
“This may be done by optimization of the hydrogen-bond network e.g., using WHATIF (Vriend, 1990), or by carrying out p K a calculations using empirical methods, such as PROPKA (Bas et al ., 2008) or physics-based methods (for review see (Nielsen, 2009))”
MethodIn silico methods to address polypharmacology: current status, applications and future perspectives
Lavecchia, A., & Cerchia, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.12.007 · Cited by 225
Ding, J., Shi, F., Xiao, C., Lin, L., Chen, L., He, C., Zhuang, X., & Chen, X. (2011) · Polymer Chemistry · doi:10.1039/c1py00360g · Cited by 228
Drug repositioning for orphan diseases
Sardana, D., Zhu, C., Zhang, M., Gudivada, R. C., Yang, L., & Jegga, A. G. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr021 · Cited by 228
“[52] predicted the off-targets for marketed drugs by mining both the 2D structure of the drugs and the side effects on the drug label.”
BackgroundPROMISCUOUS: a database for network-based drug-repositioning
von Eichborn, J., Murgueitio, M. S., Dunkel, M., Koerner, S., Bourne, P. E., & Preissner, R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1037 · Cited by 225
Integrative methods for analyzing big data in precision medicine
Gligorijević, V., Malod‐Dognin, N., & Pržulj, N. (2016) · PROTEOMICS · doi:10.1002/pmic.201500396 · Cited by 216
“chemical similarity [149], similarity between gene expressions induced by drug actions [74], or drug side-effect similarity [150]) to group drugs and infer a novel drug candidate for repurposing from the group that can perform the same action as other drugs in the group.”
BackgroundDu, K., Feng, J., Gao, X., & Zhang, H. (2022) · Light: Science & Applications · doi:10.1038/s41377-022-00871-z · Cited by 216
The Emerging Paradigm of Network Medicine in the Study of Human Disease
Chan, S. Y., & Loscalzo, J. (2012) · Circulation Research · doi:10.1161/circresaha.111.258541 · Cited by 214
“66 Taken together, these drugs may only modestly affect disease phenotype.”
BackgroundXu, H., Aldrich, M. C., Chen, Q., Liu, H., Peterson, N. B., Dai, Q., Levy, M., Shah, A., Han, X., Ruan, X., et al. (2015) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2014-002649 · Cited by 218
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
Kumar, R., Crouthamel, M.-C., Rominger, D. H., Gontarek, R. R., Tummino, P. J., Levin, R. A., & King, A. G. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605366 · Cited by 218
“Off-target activity of drugs often results in unwanted and generally harmful effects, and a better understanding of the target profile of drugs can help design agents that may avoid/minimize activities against undesired targets (Liebler and Guengerich, 2005; Campillos et al, 2008).”
BackgroundInfluentialCombining Drug and Gene Similarity Measures for Drug-Target Elucidation
Perlman, L., Gottlieb, A., Atias, N., Ruppin, E., & Sharan, R. (2011) · Journal of Computational Biology · doi:10.1089/cmb.2010.0213 · Cited by 218
“The use of pharmacological information is limited to marketed drugs whose indication/side-effect information is available [10].”
InfluentialWeth, F. R., Hoggarth, G. B., Weth, A. F., Paterson, E., White, M. P. J., Tan, S. T., Peng, L., & Gray, C. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02502-9 · Cited by 197
Relating drug–protein interaction network with drug side effects
Mizutani, S., Pauwels, E., Stoven, V., Goto, S., & Yamanishi, Y. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts383 · Cited by 211
“(2005) performed biological spectra-based approach to investigate the correlation based on their biological spectra (i.e. their ability to inhibit of 92 selected proteins) and revealed a correlation e c m r structures of the corresponding drugs and their biological similar side effects (Fliri et al…”
Predicting drug-target interactions using restricted Boltzmann machines
Wang, Y., & Zeng, J. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt234 · Cited by 211
“A regularized least square al-gorithm was proposed in van Laarhoven et al .”
Method
Metadata
- Authors
- Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P.
- Affiliations
- European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany.
- Max Delbrück Center (DE)
- Corresponding author
- Kuhn, Michael
- Venue
- Science
- Published
- 2008-07-11
- Volume
- 321
- Issue
- 5886
- Pages
- 263-266
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2154896031
- Cited by
- 1,248
- References
- 27
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 42 · 2023: 35 · 2022: 70 · 2021: 64 · 2020: 73 · 2019: 91 · 2018: 81 · 2017: 67 · 2016: 93 · 2015: 102 · 2014: 92 · 2013: 95 · 2012: 105
- FWCI
- 82.73
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Keywords
- drug target identification, adverse drug reactions, phenotypic similarity, drug repurposing, drug-target interactions, marketed drugs
- MeSH terms
- Algorithms, Chemistry, Pharmaceutical, Drug Labeling, Drug Evaluation, Preclinical, Drug Therapy, Pharmaceutical Preparations, Humans, Probability, Proteins, Databases, Factual, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.